Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Malignant Disease × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 80 Carcinoma, Non-Small-Cell Lung 76 Neoplasms 71 Ovarian Neoplasms 67 Neoplasm Metastasis 30 Fallopian Tube Neoplasms 30 Carcinoma, Ovarian Epithelial 29 Lung Neoplasms 26 Unspecified Adult Solid Tumor, Protocol Specific 24 Triple Negative Breast Neoplasms 20 Endometrial Neoplasms 19 Esophageal Neoplasms 18 Stomach Neoplasms 16 Colorectal Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 13 Head and Neck Neoplasms 13 Solid Tumors 12 Small Cell Lung Carcinoma 10 Melanoma 10 Pancreatic Neoplasms 9 Uterine Cervical Neoplasms 8 Prostatic Neoplasms 8 Lymphoma, Non-Hodgkin 8 Lymphoma, Large B-Cell, Diffuse 8 Lymphoma 8 Carcinoma, Renal Cell 8 Carcinoma 8 Brenner Tumor 8 Urinary Bladder Neoplasms 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡